Skip to Content
Søk Menu
Välkommen till lungcancer

Få de senaste artiklarna och MEDtalks om lungcancer.

Senaste nytt om lung cancer

A New Treatment Breakthrough for EGFR-mutated Lung Cancer

  • / Seppo W. Langer

Jens Benn’s Encounter with Heine Was Pivotal in His Choice of Lung Oncology

/ Jens Benn Sørensen / Amanda Feldballe Bernholm
Lungcancer
Matilde Grupe Frost

Gender-Based Outcomes in Advanced NSCLC

/ Matilde Grupe Frost
LungcancerNSCLC Play the Video

Swedish and Nordic Lung Cancer Insights – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungcancer

Lung Cancer Insights: What’s New in the Field – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungcancer

Lung Cancer highlights

Lung Cancer Insights: What’s New in the Field

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungcancer

MEDtalks

Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lungcancer Play the Video
Pasi Jänne

New Class of Medicines Emerge as Potential Therapies in MTAP-Deleted NSCLC

/ Pasi Jänne
LungcancerNSCLCWCLC25 Play the Video
Michael Stenger

WCLC 2025: Lung Cancer Screening and Early Results from the Danish PLUS Trial

/ Michael Stenger
LungcancerWCLC25 Play the Video
Maria Silvoniemi

Clinical Dilemmas in the Management of NSCLC Without Driver Mutations

/ Maria Silvoniemi
LungcancerNSCLC Play the Video
Luis Paz-Ares

ASCO 2025: Lurbinectedin–Atezolizumab Improves Survival in SCLC

/ Luis Paz-Ares
ASCO25Lungcancer Play the Video
Miriam Grønberg

Treatment Timing Impacts Survival in Limited Stage Small Cell Lung Cancer

/ Miriam Grønberg
Lungcancer Play the Video
Load more

Artiklar

New Data Support Osimertinib as a Backbone Treatment for EGFRm Advanced NSCLC

/ Jan Andreasen
LungcancerNSCLCWCLC25

Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: PALOMA-2 Update

/ Jan Andreasen
LungcancerNSCLCWCLC25

Första linjens NSCLC utan cancerdrivande mutationer: praktik, brister och kostnader

/ Ronny Öhman / Jan Andreasen
LungcancerNSCLC

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ BestPractice Nordic
ESMO24Lungcancer

No Major Breakthroughs in Lung Cancer Compared to ESMO 2023

/ BestPractice Nordic
ESMO24Lungcancer

CheckMate 227: 6-year data on the treatment of locally advanced NSCLC with Opdivo and Yervoy  

/ BestPractice Nordic
LungcancerNSCLCWCLC23
Back to top